Ataxia

Ataxia is a genetic disorder associated with chromosomal abnormalities that affect the nervous system's function, leading to impaired coordination of movement. It's a heterogeneous group of diseases classified into various types like hereditary ataxia, autoimmune ataxia, and metabolic ataxia, among others. Ataxia impacts different parts of the body, such as the cerebellum, spinal cord, peripheral nerves, and brainstem. Common symptoms include unsteady gait, nystagmus, dysarthria, hypotonia, and cognitive impairment. The severity and progression of ataxia vary based on the disorder's type and cause.

Clinical Manifestations

Clinical ManifestationsThe clinical manifestations of ataxia vary depending on the type, cause, and affected parts of the nervous system. The most common symptom is an unsteady gait, characterized by a wide-based stance, irregular steps, and difficulty in maintaining balance. Additional symptoms include nystagmus, involuntary eye movements affecting vision; dysarthria, slurred or unclear speech; hypotonia, reduced muscle tone and strength; and cognitive impairment, including memory decline, attention deficits, and executive function problems. Some types of ataxias may also present with features such as seizures, sensory loss, dystonia, or spasticity.

Different types of ataxias exhibit distinct clinical characteristics crucial for diagnosis and classification. For instance, hereditary ataxia comprises inherited disorders caused by mutations in genes affecting the cerebellum or its connections. Hereditary ataxia further categorizes into autosomal dominant ataxia (e.g., spinocerebellar ataxia), autosomal recessive ataxia (e.g., Friedreich’s ataxia), and X-linked ataxia (e.g., fragile X-associated tremor/ataxia syndrome). Autoimmune ataxia involves disorders resulting from an abnormal immune response targeting the cerebellum or its connections. This type of ataxia can be associated with other autoimmune diseases (e.g., celiac disease, multiple sclerosis, or paraneoplastic syndrome) or be idiopathic (e.g., gluten ataxia or anti-GAD antibody ataxia). Metabolic ataxia stems from defects in metabolizing certain substances affecting the cerebellum's function or structure. It can result from enzyme deficiencies (e.g., maple syrup urine disease), mitochondrial disorders (e.g., Leigh syndrome), or exposure to toxic substances (e.g., alcohol or drugs).

Clinical Diagnosis

Clinical DiagnosisDiagnosing ataxia requires a combination of techniques capable of identifying the genetic, chromosomal, and biochemical abnormalities causing the disorder. The most common method is polymerase chain reaction (PCR), amplifying and analyzing specific DNA sequences associated with ataxia. PCR can detect mutations in genes causing hereditary ataxia, such as SCA1, SCA2, SCA3, FRDA, FXTAS, etc. Additionally, it can identify chromosomal abnormalities causing ataxia, such as trisomy 21, deletion 5p, duplication 15q, etc. PCR can be performed on blood or tissue samples from affected individuals or their relatives.

Another diagnostic method for ataxia is electrophoresis, separating and analyzing molecules based on size and charge. Electrophoresis can detect biochemical markers indicating metabolic ataxia, such as amino acids, organic acids, lactate, pyruvate, etc. It can also identify protein abnormalities affecting the cerebellum's function or structure, such as alpha-fetoprotein, albumin, transferrin, etc. Electrophoresis can be conducted on blood or urine samples from affected individuals. Additional techniques used in ataxia diagnosis include cytogenetics, examining chromosome structure and number under a microscope; prenatal diagnosis, detecting genetic or chromosomal abnormalities in the fetus before birth; and high-performance liquid chromatography (HPLC), separating and analyzing complex mixtures of molecules. These methods can offer further insights into the type and cause of ataxia in specific cases.

Treatment Methods

Treatment MethodsThe treatment of ataxia depends on the type and cause of the disorder, as well as the severity and progression of the symptoms. The primary goal of treatment is to improve the quality of life and reduce the complications of the disorder. The most common method of treatment is pharmacotherapy, which involves using drugs to alleviate the symptoms or address the underlying cause of ataxia. Pharmacotherapy may include anticonvulsants, antidepressants, antispasmodics, antioxidants, chelating agents, and more. These medications aim to control seizures, mood disorders, muscle spasms, oxidative stress, metal accumulation, and other related issues. However, it's important to note that pharmacotherapy's efficacy is limited and may lead to side effects in some cases.

Fig.1 Multidisciplinary approach to the management of patients with ataxia and hypogonadism. (De Michele G, 2023)

Another method of treatment is physiotherapy, which involves the use of physical exercises and devices to improve the function and mobility of affected individuals. Physiotherapy may include balance training, gait training, coordination training, strength training, and more. It aims to enhance posture, stability, walking, movement accuracy, muscle tone, and can also prevent or delay the deterioration of the nervous system and muscles. However, physiotherapy demands regular and intensive practice and may not be accessible or affordable for some individuals.

A promising avenue of treatment is gene therapy, which utilizes genetic material to modify or replace the defective genes causing ataxia. Gene therapy methods encompass viral vectors, non-viral vectors, gene editing, gene silencing, and more. This approach has the potential to correct the genetic or chromosomal abnormalities affecting the function or structure of the cerebellum or its connections. Additionally, gene therapy can potentially restore the normal expression or activity of proteins involved in ataxia. However, gene therapy is still in its early stages and encounters numerous challenges and risks related to safety, efficiency, specificity, delivery, and regulation.

References

1. Anheim M, et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain. 2009 Oct;132(Pt 10):2688-98.
2. De Michele G, et al. Ataxia and Hypogonadism: a Review of the Associated Genes and Syndromes. Cerebellum. 2023 Mar 30.
3. Klockgether T, et al. A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiol Dis. 2008 Jan;29(1):92-102.
4. Lynch DR, et al. Friedreich ataxia: current pathophysiological issues and therapeutic outlook. Nat Rev Neurol. 2020 Feb;16(2):107-121.
5. Manto M, et al. Consensus paper: roles of the cerebellum in motor control-the diversity of ideas on cerebellar involvement in movement. Cerebellum. 2012 Jun;11(2):457-87.
6. Matilla-Dueñas A, et al. Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias. Cerebellum. 2014 Aug;13(4):269-302.
7. Mochel F, et al. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One. 2007 Jul 25;2(7):e647.
8. Pandolfo M, et al. The molecular basis of Friedreich’s ataxia and other frataxin-related diseases. Mol Genet Metab Rep. 2019 Dec 5;22:100524.
9. Subramony SH, et al. Autosomal dominant cerebellar ataxia type I: a review of the phenotypic and genotypic characteristics. Orphanet J Rare Dis .2019 May 14;14(1):95.